Coherus BioSciences (NASDAQ:CHRS) just reported results for the second quarter of 2024.
- Coherus BioSciences reported earnings per share of -14 cents. This was above the analyst estimate for EPS of -16 cents.
- The company reported revenue of $64.98 million.
- This was 1.28% better than the analyst estimate for revenue of $64.16 million.